The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Consensus recommendations for the management of pediatric psoriasis from the Spanish AEDV
Psoriasis is one of the most common dermatological conditions to affect children and can negatively impact development and QoL. Therefore, there is a need for evidence-based recommendations to guide the care of pediatric patients with psoriasis.1
The Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis and Pediatric Working Groups developed a consensus document using a nominal group methodology combined with a systematic literature review. Experts were selected to provide insights based on their experience, with the aim of developing recommendations to act as guidance for dermatologists to support optimal therapy selection and standardize clinical practice for pediatric patients with psoriasis.1
|
Key learnings |
| Pediatric psoriasis significantly impacts on QoL and is associated with multiple comorbidities, including psoriatic arthritis, obesity, depression, and metabolic syndrome, necessitating individualized treatment with consideration of severity, patient age, comorbidities, preferences, and drug availability. |
| Topical corticosteroids, calcipotriol, and biologic therapies (including etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab) are recommended, with biologics increasingly preferred for moderate-to-severe cases, depending on patient characteristics and disease severity. |
| Complete clearance (PASI100) is the optimal aim, but PASI90 or PASI75 may be acceptable in refractory cases. Long-term disease control is critical in children due to their ongoing physical and psychological development. Vaccination is also considered essential for infection control. |
| Pediatric psoriasis is a multisystemic disease with unique clinical presentations and comorbidities, necessitating thorough assessment, including disease severity, QoL impact, and therapeutic response. Multidisciplinary care, including dermatologists, pediatricians, and psychologists, is essential to optimize outcomes. |
Abbreviations: PASI, Psoriasis Area and Severity Index; QoL, quality of life.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
